PL372993A1 - Zastosowanie specyficznej pochodnej aminy cyklicznej lub jej farmaceutycznie dopuszczalnych soli doleczenia lub zapobiegania niewydolności serca - Google Patents

Zastosowanie specyficznej pochodnej aminy cyklicznej lub jej farmaceutycznie dopuszczalnych soli doleczenia lub zapobiegania niewydolności serca

Info

Publication number
PL372993A1
PL372993A1 PL03372993A PL37299303A PL372993A1 PL 372993 A1 PL372993 A1 PL 372993A1 PL 03372993 A PL03372993 A PL 03372993A PL 37299303 A PL37299303 A PL 37299303A PL 372993 A1 PL372993 A1 PL 372993A1
Authority
PL
Poland
Prior art keywords
prevention
treatment
pharmaceutically acceptable
acceptable salts
heart failure
Prior art date
Application number
PL03372993A
Other languages
English (en)
Other versions
PL214716B1 (pl
Inventor
Brian Guth
Juergen Daemmgen
Randolph Seidler
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL372993(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of PL372993A1 publication Critical patent/PL372993A1/pl
Publication of PL214716B1 publication Critical patent/PL214716B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL372993A 2002-07-25 2003-07-21 Zastosowanie cilobradyny lub jej farmaceutycznie dopuszczalnej soli do wytwarzania kompozycji farmaceutycznej do leczenia lub zapobiegania niewydolnosci serca PL214716B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016602A EP1362590B1 (en) 2002-07-25 2002-07-25 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Publications (2)

Publication Number Publication Date
PL372993A1 true PL372993A1 (pl) 2005-08-08
PL214716B1 PL214716B1 (pl) 2013-09-30

Family

ID=29265956

Family Applications (1)

Application Number Title Priority Date Filing Date
PL372993A PL214716B1 (pl) 2002-07-25 2003-07-21 Zastosowanie cilobradyny lub jej farmaceutycznie dopuszczalnej soli do wytwarzania kompozycji farmaceutycznej do leczenia lub zapobiegania niewydolnosci serca

Country Status (29)

Country Link
US (1) US20130317008A1 (pl)
EP (2) EP1362590B1 (pl)
JP (3) JP2005533853A (pl)
KR (1) KR20050074432A (pl)
CN (1) CN100502874C (pl)
AR (1) AR040690A1 (pl)
AT (2) ATE257384T1 (pl)
AU (1) AU2003254554B8 (pl)
BR (1) BR0312852A (pl)
CA (1) CA2493208C (pl)
CO (1) CO5700723A2 (pl)
CY (1) CY1112173T1 (pl)
DE (1) DE60200160T2 (pl)
DK (2) DK1362590T3 (pl)
ES (2) ES2211846T3 (pl)
HR (1) HRP20050075B1 (pl)
MX (1) MXPA05000617A (pl)
MY (1) MY128529A (pl)
NZ (1) NZ538424A (pl)
PE (1) PE20040706A1 (pl)
PL (1) PL214716B1 (pl)
PT (2) PT1362590E (pl)
SA (1) SA03240350B1 (pl)
SI (2) SI1362590T1 (pl)
TR (1) TR200400127T4 (pl)
TW (1) TWI319321B (pl)
UY (1) UY27910A1 (pl)
WO (1) WO2004011006A1 (pl)
ZA (1) ZA200500084B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2211846T3 (es) * 2002-07-25 2004-07-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Uso de cilobradina o sus sales farmaceuticamente aceptables para el tratamiento o la prevencion de la insuficiencia cardiaca.
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US20090247572A1 (en) * 2005-08-23 2009-10-01 Koichi Wada Agent for treating atrial fibrillation
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2927538B1 (fr) 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
AR089646A1 (es) 2011-08-12 2014-09-10 Boehringer Ingelheim Vetmed Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) * 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
JP4240173B2 (ja) * 1998-06-03 2009-03-18 日産化学工業株式会社 インダン誘導体
EP1186601B1 (en) * 1999-06-03 2004-03-24 Yamanouchi Pharmaceutical Co. Ltd. Novel isoquinoline derivatives or salts thereof
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
ES2211846T3 (es) * 2002-07-25 2004-07-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Uso de cilobradina o sus sales farmaceuticamente aceptables para el tratamiento o la prevencion de la insuficiencia cardiaca.

Also Published As

Publication number Publication date
DE60200160T2 (de) 2004-11-04
US20130317008A1 (en) 2013-11-28
BR0312852A (pt) 2005-04-19
ES2211846T3 (es) 2004-07-16
SA03240350B1 (ar) 2007-10-29
ES2367109T3 (es) 2011-10-28
AR040690A1 (es) 2005-04-13
JP2005533853A (ja) 2005-11-10
SI1362590T1 (sl) 2004-04-30
CO5700723A2 (es) 2006-11-30
EP1362590A8 (en) 2004-02-25
CN100502874C (zh) 2009-06-24
EP1362590A1 (en) 2003-11-19
AU2003254554A1 (en) 2004-02-16
JP2013166781A (ja) 2013-08-29
TWI319321B (en) 2010-01-11
ATE257384T1 (de) 2004-01-15
EP1362590B1 (en) 2004-01-07
DK1362590T3 (da) 2004-03-29
DK1534296T3 (da) 2011-08-15
KR20050074432A (ko) 2005-07-18
WO2004011006A1 (en) 2004-02-05
AU2003254554B8 (en) 2009-02-26
MXPA05000617A (es) 2005-08-19
TR200400127T4 (tr) 2004-02-23
PT1362590E (pt) 2004-05-31
PE20040706A1 (es) 2004-12-06
AU2003254554B2 (en) 2009-01-29
DE60200160D1 (de) 2004-02-12
MY128529A (en) 2007-02-28
EP1534296A1 (en) 2005-06-01
ATE510543T1 (de) 2011-06-15
PL214716B1 (pl) 2013-09-30
HRP20050075B1 (hr) 2013-12-20
NZ538424A (en) 2006-10-27
CA2493208C (en) 2011-11-01
TW200412974A (en) 2004-08-01
CY1112173T1 (el) 2015-12-09
UY27910A1 (es) 2004-02-27
CN1671392A (zh) 2005-09-21
ZA200500084B (en) 2005-10-26
EP1534296B1 (en) 2011-05-25
HRP20050075A2 (en) 2005-12-31
SI1534296T1 (sl) 2011-09-30
PT1534296E (pt) 2011-08-18
CA2493208A1 (en) 2004-02-05
JP2009256379A (ja) 2009-11-05

Similar Documents

Publication Publication Date Title
PL375964A1 (pl) Zastosowanie pochodnych indolilu do wytwarzania leku do leczenia kataru siennego
DE60329001D1 (en) 8-hydroxychinolinderivate
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
AU2003257613A1 (en) Catheter for treating irregular heart pulse
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
IL213806A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
PL377467A1 (pl) Aromatyczne związki jako środki przeciwzapalne, immunomodulujące i antyproliferacyjne
TWI319321B (en) Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
WO2007126898A8 (en) Use of ladostigil for the treatment of schizophrenia
PL378537A1 (pl) Zastosowanie propionylo L-karnityny do otrzymywania leku do leczenia glaukomii
AU1522101A (en) Heparanase inhibitors for the treatment of heart failure
AU2003209542A8 (en) Use of s-substituted l-crysteine for the manufacture of a medicament for the treatment of dermatological disorders
AU2003301758A8 (en) Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders
EP1579867A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OF ISCHEMIC HEART FAILURE
WO2004035031A3 (en) Treatment of uveal melanoma
HRP20041159A2 (en) Combination for the treatment of airway disorders
AU2003269985A8 (en) Methods for increasing the rate of heart muscle contraction
SI1553938T1 (sl) Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma
IL164388A0 (en) Use of ranolazine for the preparation of a medicament for the treatment of arrhymias
WO2003004019A8 (en) Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia
SI1408977T1 (sl) Kombinacijska terapija za zdravljenje srcne insuficence
AU2002345140A1 (en) A combination therapy for the treatment of heart failure
GB0204683D0 (en) Pharmaceutical salts
GB0211413D0 (en) Combination therapy for respiratory disorders
GB0224328D0 (en) Combination therapy for respiratory disorders